Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme/Isis On Track To Submit Severe High Cholesterol Drug Mipomersen In 1H 2011

This article was originally published in The Pink Sheet Daily

Executive Summary

The second-generation antisense drug is four for four in positive Phase III outcomes, but in addition to lowered cholesterol, patients in those studies had elevated liver enzymes, leaving observers to wonder whether FDA will consider the side effect a manageable trade-off for filling an unmet need.

You may also be interested in...

Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation

French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.

Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely

Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.

Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger

Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts